Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours

Technology appraisal guidance
Reference number: TA209
Published: 24 November 2010

Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): consultee comments

Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): Novartis (manufacturer) response
Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): Royal College of Nursing response
Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): Royal College of Pathologists response
Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): Royal College of Physicians (on behalf of many) response to ACD
Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): Royal College of Physicians (on behalf of many) response to evaluation report

This page was last updated: 13 September 2010